You are here:
PBL News »
LSBC Option to Expand Licence Agreement
Large Scale Biology Corporation Exercises Option to Expand Licensing Agreement in Plant Functional Genomics with Plant Bioscience Limited
“We anticipate many commercial applications for LSBC technology in agricultural markets and expect our expanded alliance with PBL to accelerate our progress in making solid deals,” said Robert L Erwin, Chairman and CEO of LSBC. “Adding the strength of our alliance with PBL to our record of three years in a recently concluded exclusive research collaboration in agricultural genomics, we are now positioned to expand our agricultural base.” Among its broad genomic technologies, LSBC offers exclusive use of monocot GENEWARE® vectors, gene discoveries for certain dicot crops and rights to collaborative gene discoveries for use in forestry, ornamentals and turfgrass, the genus Nicotiana, and all pharmaceutical applications.
Dr Guy della-Cioppa, LSBC Vice President of Business Development, characterised today’s announcement as “a strong message to agricultural partners about the extent of our plant capabilities.” The expanded field of use under the PBL license, he said, “allows LSBC’s patented GENEWARE® functional genomics technology to include monocots as well as dicots as we introduce gene sequences rapidly into mature plants in just a matter of days, not months. We then study overexpression gain-of-function phenotypes or gene silencing (eg RNAi) loss-of-function phenotypes.”
In Britain, Dr Jan Chojecki, Managing Director of Plant Bioscience Ltd, called the expanded agreement “the ideal combination of two exceptionally strong technology packages resulting in a full platform of state-of-the-science options for all aspects of plant functional genomics and viral-based manufacture of valuable compounds in plants.”
About Large Scale Biology Corporation
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on our current plans, expectations, estimates, and projections and management's beliefs about our future performance. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates” or variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict and which may cause our actual results and performance to differ materially from those expressed or forecasted in any such forward-looking statements. For a further list and description of such risks and uncertainties see the reports filed by Large Scale Biology Corporation with the Securities Exchange Commission. Unless required by law, Large Scale Biology Corporation undertakes no obligation to update publicly any forward-looking statements.
PBL is pleased to announce that it has been successful in three separate bids for awards worth a total of nearly £4 million under the UK Government Office of Science and Technology Knowledge Exploitation Funding programme. The awards will enable PBL to expand its technology transfer and business development activities in plant and microbial sciences.
Expansion of Business Development Activities
ICENI Fund for New Companies
Although the ICENI Fund will invest in a range of science based opportunities, bioscience-based entities funded by the ICENI will have the opportunity to establish their operations in the Norwich Bio-Incubator, a purpose built incubator building providing state-of-the-art lab and office space for bioscience businesses.
Granted US Patents for Flowering Gene
Following the recent grant in the US of Patent No. 6265637, PBL now has three granted US patents for the genetic control of flowering time. This new patent covers the LHY (late elongated hypocotyl) gene which is required for the response to photoperiod. This work was carried out by George Coupland and Robert Schaffer at the John Innes Centre, Norwich. It complements two US patents granted to PBL last year involving control of flowering time genes FCA (No. 6140085) and CO (No. 6077994).
PBL is committed to developing its portfolio of flowering genes, which currently consists of applications and granted patents covering ten genes involved in the control of flowering.
For further information on LHY, or any other PBL flowering genes, please contact Jan Chojecki.
New Major Licence Agreement
PBL completes major licence of its viral derived gene-silencing portfolio for plant functional genomics
LSBC is a natural choice of partner for this technology given their complementary strengths in plant viral-expression vectors and track record in using this platform to underpin research and technology alliances with major players in the ag-biotech industry. Under the terms of the licence LSBC has committed to develop the combined platform of technologies and will be seeking to use this to complete new collaborations with industrial customers. The agreement also includes a commitment from LSBC to fund a significant program of research at the Sainsbury Laboratory.
Click here for full press release.
PBL Microbiology Success
PBL is delighted to announce that it has been successful in its application for an award under the DTI's Biotechnology Exploitation Platform (BEP) to establish a new team to provide intellectual property management and technology transfer services to the UK's microbiology research community.
The platform partners with PBL in this "UK MicroBEP" initiative are the John Innes Centre and the Institute of Food Research, Norwich, and PBL has also received interest from ten other UK Universities. The award, which is staged over four years, will provide matching funds for PBL to establish a team of three IP/Tech Transfer experts focussed on emerging microbial sciences.
If you wish to learn more about the UK MicroBEP, or any other services offered by PBL, please contact Jan Chojecki on 01603 456500 or firstname.lastname@example.org.
Granted US Patents
With Cf-9 already achieving granted US patent status, PBL shows that it's a serious competitor in the US with a further two granted patents now added to its disease resistance portfolio.
Cf-4 : Granted US patent on tomato Cf-4 (USP 6225527 B) - provides PBL with a useful element of protection for Cf-4-like polypeptides and plants containing them. This patent provides generic cover for Cf-4 sequences from other plants and is not necessarily restricted to tomato sequences per se.
Cf-5 : Granted US patent on tomato Cf-5 (USP 6225532 B1) - also provides PBL with further protection on a disease resistant element.
PBL is Growing
RPW8 genes published in Science
PBL is pleased to report the publication in Science of the cloning of the RPW8 genes by Dr John Turner and colleagues at the University of East Anglia. The Arabidopsis thaliana locus RESISTANCE TO POWDERY MILDEW8 (RPW8) contains two naturally polymorphic, dominant R genes, RPW8.1 and RPW8.2, which individually control resistance to a broad range of powdery mildew pathogens. Although the predicted RPW8.1 and RPW8.2 proteins are different from the previously characterised R proteins, they induce localized, salicylic acid-dependent defenses similar to those induced by R genes that control specific resistance. The RPW8 genes will have utility in engineering broad spectrum powdery mildew resistance in crop plants. For further information about commercial opportunities please contact Jan Chojecki at PBL.
|©2017 PBL Technology|